You're using an outdated browser. This website will not display correctly and some features will not work.
Learn more about the browsers we support for a faster and safer online experience.

 

ontario regulation 21/13

made under the

Drug Interchangeability and Dispensing Fee Act

Made: January 9, 2013
Filed: January 23, 2013
Published on e-Laws: January 23, 2013
Printed in The Ontario Gazette: February 9, 2013

Amending Reg. 935 of R.R.O. 1990

(GENERAL)

1. Subsection 6 (8) of Regulation 935 of the Revised Regulations of Ontario, 1990 is revoked and the following substituted:

(8) A strength and dosage form of a drug product that contains oxycodone as the only active ingredient and that is a long-acting product that has been formulated in a solid dosage form for oral administration shall not be designated as interchangeable unless the following conditions are met:

1. There must be evidence satisfactory to the executive officer that the drug product exhibits one or more physiochemical properties that, when compared to drugs without the property or properties, make the drug product,

i. significantly more difficult to alter, break, crush, chew, dissolve or otherwise manipulate in such a way that it could be misused, abused or put to an intended use that is different than the use for which it is prescribed, or

ii. significantly less effective and less likely to be misused, abused or put to an intended use that is different than the use for which it is prescribed, if the product is altered, broken, crushed, chewed, dissolved or otherwise manipulated.

2. The evidence referred to in paragraph 1 must be demonstrated by,

i. in vitro testing,

ii. in vivo testing,

iii. another form of testing of equivalent reliability, or

iv. a combination of any of the forms of testing mentioned in subparagraphs i to iii.

Commencement

2. This Regulation is deemed to have come into force on November 23, 2012.